Synlogic Dirección

Dirección controles de criterios 2/4

El CEO de Synlogic es Tony Awad , nombrado en Mar 2024, tiene una permanencia de menos de un año. compensación anual total es $701.53K, compuesta por 60.3% salario y 39.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.29% de las acciones de la empresa, por valor de $49.10K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 8 años, respectivamente.

Información clave

Tony Awad

Chief Executive Officer (CEO)

US$701.5k

Compensación total

Porcentaje del salario del CEO	60.3%
Permanencia del CEO	less than a year
Participación del CEO	0.3%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tony Awad en comparación con los beneficios de Synlogic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$73m
Dec 31 2023	US$702k	US$423k	-US$57m
Sep 30 2023	n/a	n/a	-US$59m
Jun 30 2023	n/a	n/a	-US$65m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$876k	US$411k	-US$66m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$811k	US$391k	-US$61m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$723k	US$359k	-US$59m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$57m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$809k	US$325k	-US$51m

Compensación vs. Mercado: La compensación total de Tony($USD701.53K) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD367.29K).

Compensación vs. Ingresos: La compensación de Tony ha sido consistente con los resultados de la empresa en el último año.

CEO

Tony Awad (44 yo)

less than a year

Permanencia

US$701,534

Compensación

Mr. Antoine Awad, also known as Tony, served as Chief Operating Officer at Synlogic, Inc. since July 2020 and was its Head of Technical Operations since December 12, 2018 until 2020 and serves as Principal...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Antoine Awad	Principal Executive Officer	less than a year	US$701.53k	0.29% $ 49.1k
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Mary Dooley	VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer	less than a year	sin datos	0.13% $ 22.0k
Ajay Munshi	Vice President of Corporate Development	no data	sin datos	sin datos
Molly Harper	Chief Business Officer	3.2yrs	sin datos	sin datos
Neal Sondheimer	VP & Head of Clinical	1.4yrs	sin datos	sin datos
Mylene Perreault	VP & Head of Research	1.8yrs	sin datos	sin datos
Jose-Carlos Gutierrez-Ramos	Advisor	no data	US$1.39m	sin datos

1.4yrs

Permanencia media

45.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0A8U no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Shea	Independent Director	7.3yrs	US$65.70k	0.0043% $ 724.2
Peter Barrett	Independent Chairman of the Board	10.3yrs	US$92.20k	0% $ 0
Edward Mathers	Independent Director	12.1yrs	US$55.70k	0% $ 0
Michael Heffernan	Independent Director	3.9yrs	US$66.20k	0% $ 0
Nick Leschly	Independent Director	8.7yrs	US$55.70k	0.013% $ 2.2k
Paul Miller	Member Scientific Advisory Board	no data	US$956.81k	sin datos
Kristala Lanett Prather	Member of Scientific Advisory Board	no data	sin datos	sin datos
Cammie Lesser	Member of Scientific Advisory Board	no data	sin datos	sin datos
Christopher Voigt	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Flynn	Independent Director	less than a year	sin datos	sin datos

8.0yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 0A8U se considera experimentada (8 años de antigüedad promedio).

Synlogic Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Synlogic, Inc., Annual General Meeting, Dec 04, 2024

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Recent updates

Synlogic, Inc., Annual General Meeting, Dec 04, 2024

New major risk - Share price stability

New major risk - Financial position

Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Third quarter 2023 earnings released: US$2.57 loss per share (vs US$3.73 loss in 3Q 2022)

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

High number of new directors

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

High number of new directors

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad